Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
Łukasz Biegała, Arkadiusz Gajek, Agnieszka Marczak, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188633-188633
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

New Horizons in Lung Cancer Management Through ATR/CHK1 Pathway Modulation
Riya Thapa, Obaid Afzal, Asif Ahmad Bhat, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 19, pp. 1807-1818
Open Access | Times Cited: 50
Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer
Soumi Mukherjee, Gurjit Kaur Bhatti, Ravindresh Chhabra, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 160, pp. 114398-114398
Open Access | Times Cited: 40
Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer
Fangyan Gao, Yueyao Wu, Runtian Wang, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2685-2697
Open Access | Times Cited: 7
Review: Protein O-GlcNAcylation regulates DNA damage response: A novel target for cancer therapy
Zhuang Zhu, Shaoming Li, Xiaopeng Yin, et al.
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130351-130351
Closed Access | Times Cited: 6
Olaparib-Resistant BRCA2MUT Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
Łukasz Biegała, Arkadiusz Gajek, Agnieszka Marczak, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1038-1038
Open Access | Times Cited: 16
ARID1Amutations in cancer development: mechanism and therapy
Xuewei Zhang, Yixuan Zhang, Jinyi Zhao, et al.
Carcinogenesis (2023) Vol. 44, Iss. 3, pp. 197-208
Closed Access | Times Cited: 15
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells
Łukasz Biegała, Arkadiusz Gajek, Izabela Szymczak-Pajor, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Overcoming PARP inhibitor resistance in ovarian cancer
Pamela Soberanis Pina, Stéphanie Lheureux
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 3, pp. 364-376
Closed Access | Times Cited: 11
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Philipp Harter, Christian Marth, Marie‐Ange Mouret‐Reynier, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 4
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer
Trudy Janice Philips, Britt Erickson, Stefani N. Thomas
Frontiers in Oncology (2025) Vol. 14
Open Access
Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
Michela Chiappa, Federica Guffanti, Martina Anselmi, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1807-1807
Open Access | Times Cited: 17
Biomarkers in high grade serous ovarian cancer
Mark C. Bates, Bashir M. Mohamed, F. Park Lewis, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189224-189224
Closed Access | Times Cited: 3
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Shixuan Peng, M.D. Long, Qi-Sheng Chen, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed
Xiaoyi Hu, Ce Bian, Xia Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
PARPi Decreased Primary Ovarian Cancer Organoid Growth Through Early Apoptosis and Base Excision Repair Pathway
Qi Cao, Lanyang Li, Yuqing Zhao, et al.
Cell Transplantation (2023) Vol. 32
Open Access | Times Cited: 9
Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs
Yajing Du, Lulu Luo, Xinru Xu, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2433-2433
Open Access | Times Cited: 9
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Sara Bouberhan, Liron Bar‐Peled, Yusuke Matoba, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 345-357
Open Access | Times Cited: 8
DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1
Rakesh Srivastava, Niraj Lodhi
Biomolecules (2022) Vol. 12, Iss. 3, pp. 417-417
Open Access | Times Cited: 13
Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients
Giada De Lazzari, Alena Opattová, Sabrina Arena
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
Chaohua Liu, Jiana Li, Fei Xu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Adenosine receptor A2b confers ovarian cancer survival and PARP inhibitor resistance through IL‐6‐STAT3 signalling
Liqing Chi, Lin Huan, Chunyan Zhang, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 15, pp. 2150-2164
Open Access | Times Cited: 6
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
Ruihong Dong, Ting Ding, Zhengyu Li
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 5
Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors
Valens Munyembaraga, Delphine Cyuzuzo, Tran Nhat Phong Dao, et al.
European Journal of Cancer Care (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers
Matthew Monberg, Steve Keefe, Vassiliki Karantza, et al.
Oncology and Therapy (2024)
Open Access | Times Cited: 1
LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1
Yancheng Zhong, Shuai Yang, Juan Yang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 12
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top